As the PI3K/AKT/NF-κB signaling pathway is critical for the survival or apoptosis in cisplatin-based chemotherapy in cancers and NF-κB is one of downstream targets of AKT, we assume that AKT activation might play an essential role in RMP mediated NF-κB activation. The gene discussed is URI1; the disease is cancer.